

DAEL R. GEFT, M.D.,
CURRICULUM VITAE

April 13th, 2021

PROFESSIONAL CONTACT INFORMATION

Business Address: Cedars-Sinai Medical Center
8700 Beverly Blvd
Los Angeles, CA 90048

California Heart Center
8670 Wilshire Blvd, 2nd Floor
Beverly Hills, CA 90211

Phone: (310) 248-8300
Fax: (310) 248-8333
Email: Dael.Geft@cshs.org

EDUCATION

Undergraduate

Columbia University, New York City, New York 1997-2001
B.A. Philosophy/Religion, May 2001

Medical Education

Sackler School of Medicine –New York State American Program, Tel Aviv, Israel 2001-2005
M.D., May 2005

Residency

Cedars-Sinai Medical Center, Los Angeles, California 2005 – 2008
Resident, Internal Medicine

General Cardiology Fellowship

Cedars-Sinai Medical Center, Los Angeles, CA 2009-2012
Cardiovascular Disease

Cedars-Sinai Medical Center, Los Angeles, CA 2012 – 2013
Advanced Heart Failure/Heart Transplant

LICENSURE:

California Medical License, #A102122 2007 –
Drug Enforcement Administration (DEA), FG0636324 2019 –
National Provider Identifier (NPI), 1265617187 2008 –

BOARD CERTIFICATION:

American Board of Internal Medicine, Internal Medicine 2009-2016
Certification Board of Nuclear Cardiology, Nuclear Cardiology 2012-

American Board of Internal Medicine, Cardiovascular Disease 2013-
National Board of Echocardiography, Echocardiography 2013-
American Board of Internal Medicine, Advanced Heart Failure/Transplant Cardiology 2014-

PROFESSIONAL EXPERIENCE:

Present Position:

2019 – Volunteer Clinical Instructor, University of California Los Angeles, Department of Medicine, Los Angeles, CA

2013- Advanced Heart Failure/Mechanical Circulatory Support/Transplant Cardiology
Attending, California Heart Center, Cedars-Sinai Smidt Heart Institute

2013- Associate Director, Pulmonary Hypertension Research and Education Advanced Heart
Disease, Cedars-Sinai Smidt Heart Institute

Previous Position:

1995 – 1998 Research Associate, Immunology research in the lab of Dr. Ellen Robey, UC Berkeley

2009 – 2011 Clinical Instructor, Department of Medicine, Division of Cardiology. University of
California, Los Angeles

2010 – 2011 Staff Cardiologist, Tier system. Department of Medicine, Division of Cardiology. University
of California, Los Angeles.

PROFESSIONAL ACTIVITIES:

Committee Services:

2013 – Heart Transplant Executive Committee
2013 – MCS Executive Committee

Professional Associations/Society Memberships:

2013 – International Society of Heart and Lung Transplantation
2013 – American College of Cardiology
2013 – Heart Failure Society of America
2020 – Pulmonary Hypertension Association

HONORS AND SPECIAL AWARDS:

1997 – 2001 Dean's List, Columbia University

2005 Elected Class Speaker for medical school graduation ceremony, Sackler School Medicine

2007 Standing Ovation, letter of recognition for outstanding patient care during residency,
Cedars-Sinai Medical Center

2008 Ben Newman Award for Excellence in Patient Care, Cedars-Sinai Medical Center

2010 Outstanding Fellow of the Year, Cedars-Sinai Medical Center

RESEARCH GRANTS AND FELLOWSHIPS RECEIVED:

Active/Ongoing:

Abbott **Ramzy (site PI)** **11/13/2015- Present**
MOMENTUM 3 (Multi-Center Study of Maglev Technology in Patients Undergoing MCS Therapy with
HeartMate 3™)

Role: Co-Investigator

Abbott **Ramzy (site PI)** **11/11/2016- Present**
MOMENTUM 3 CAP Multi-Center Study of Maglev Technology in Patients Undergoing MCS Therapy with HeartMate 3™ Continued Access Protocol: Post-Approval Continued Follow-up
Role: Co-Investigator

Alexion Inc. **Patel (PI)** **2014-Present**
The DUET Cardiac Trial - The De-novo Use of Eculizumab Alongside Conventional Maintenance Therapy in Presensitized Patients Receiving Cardiac Transplantation: An, Open-Label, Investigator-Initiated Pilot Trial. Investigational pilot trial to determine the safety and efficacy of the de-novo use of eculizumab to prevent symptomatic antibody (AMR \geq 1) and/or cellular mediated rejection (\geq 2 Grade 2R) in highly sensitized cardiac transplantation recipients (PRA $>$ 70%).
Role: Co-Investigator

NIH/Duke University **Kransdorf (Site PI)** **11/01/17-Present**
Entresto™ (LCZ696) In Advanced Heart Failure (Life Study). The purpose of this study is to evaluate the effects of LCZ696 (Entresto) compared to valsartan by evaluating NT-proBNP levels. The hypothesis is that patients with symptomatic heart failure due to left ventricular systolic dysfunction, treatment with LCZ696 for 24 weeks will improve NT-proBNP levels. The study is a randomized, double-blinded trial of advanced heart failure subjects.
Role: Co-Investigator

United Therapeutics **Hage (PI)** **12/29/17 – present**
Southpaw 301 - A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved Ejection Fraction (HFpEF).
Role: Co-Investigator

United Therapeutics **Hage (PI)** **12/29/17 - present**
Southpaw 302 - An Open-label Extension Study of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) Associated with Heart Failure with Preserved Ejection Fraction (HFpEF) - A Long-Term Follow-up to Study TDE-HF-30
Role: Co-Investigator

Janssen & Janssen LLC **Hage (PI)** **01/03/18- Present**
SERENADE – AC_055G202 - Heart failure with preserved ejection fraction and pulmonary vascular disease
Role: Co-Investigator

United Therapeutics **Hage (PI)** **09/11/17- Present**
RIN-PH-201 - Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease
Role: Co-Investigator

United Therapeutics **Hage (PI)** **09/12/17 - Present**
RIN-PH-202 - An Open-Label Extension Study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease

Role: Co-Investigator

California Institute for Regenerative Medicine **Lewis (PI)** **01/01/17 – Present**
ALPHA - Pulmonary Arterial Hypertension Treated with Cardiosphere-Derived Allogeneic Stem Cells
Role: Co-Investigator

Completed:

Pfizer, Inc. **Patel (Site PI)** **03/24/17-3/23/2020**
ATTR- EXT - A Phase 3 Multicenter, Randomized, Double-Blind, Extension Study To Evaluate The Safety Of Daily Oral Dosing Of Tafamidis Meglumine (Pf-06291826) 20 Mg Or 80 Mg In Subjects Diagnosed With Transthyretin Cardiomyopathy (Ttr-Cm)
Role: Co-Investigator

NIH ALL-IN Study/1U01AI136816-01 **Patel(Site PI)** **05/01/2018– 04/30/2020**
Targeting Inflammation and Alloimmunity in Heart Transplant Recipients with Tocilizumab. The primary objective of the study is to compare the efficacy of standard of care triple maintenance immunosuppression plus tocilizumab treatment versus standard of care triple maintenance immunosuppression plus placebo on outcomes as defined by a composite 1 year post-transplant endpoint of a) detection of donor-specific antibodies (DSA), b) acute cellular rejection (ACR), c) antibody mediated rejection (AMR), d) hemodynamic compromise (HDC) rejection in absence of biopsy or histological rejection, e) death, and f) retransplantation.
Role: Co-Investigator

Genzyme **Kobashigawa (PI)** **07/01/2018 – 07/01/2021**
A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (ATG): A 12-month, single center, randomized, open-label study of efficacy comparing immediate treatment with and without Thymoglobulin® 1.5 mg/kg/d for 5 consecutive days in heart transplant recipients. The purpose of this study is to definitively establish Thymoglobulin's potential efficacy in preventing cardiac allograft vasculopathy.
Role: Co-Investigator

Alnylam Pharmaceuticals **Patel (site PI)** **02/01/2020 – 01/31/2022**
APOLLO-B - A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
Role: Co-Investigator

Eidos Pharmaceuticals **Patel (site PI)** **05/21/2019 – 05/20/2022**
Eidos AG10-301/ATTRIBUTE-CM - aprospective, randomized, multicenter, parallel-group study will evaluate the efficacy and safety of AG10 in symptomatic subjects compared to placebo, administered on a background of stable heart failure therapy
Role: Co-Investigator

TransMedics **Esmailian (PI)** **09/11/2019 – 09/10/2022**

OCS-CAR-121918 - Continued Access Protocol to collect additional evidence to evaluate the Safety and Effectiveness of The Portable Organ Care System (OCS™) Heart For Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation (Heart EXPAND CAP

Role: Co-Investigator

RESEARCH FOCUS AND INTERESTS:

I am actively involved in both clinical practice as well as research and education in the fields of advanced heart failure, transplant, mechanical circulatory support and pulmonary hypertension. I am currently the Associate Director of Pulmonary Hypertension research and education at the Cedars-Sinai Smidt Heart Institute. I have publications in journals such as the Journal of heart and Lung Transplant and have written book chapters on pulmonary hypertension and cancer. My main focus is on management of pulmonary hypertension and heart failure and I have spoken at various conferences and symposia on these topics. I am also involved in a number of ongoing clinical trials for CHF (medication and device based), immunosuppression for heart transplantation as well as management of pulmonary hypertension with novel agents and stem cells.

INVITED LECTURES AND PRESENTATIONS:

1. Case Presentation, PHA Preceptorship. Sofitel Los Angeles at Beverly Hills, Los Angeles, CA. December 13, 2019
2. “Cardiomyopathy/Heart Failure: The Most Up to Date – State of The Art Ways to Treat Heart Failure and Maintain Quality of Life,” St. Mary Medical Center Lecture, Apple Valley, CA. March 13, 2020.

TEACHING ACTIVITIES:

Clinical Teaching

1. In-patient rounds with UCLA medical students at Cedars-Sinai Medical Center, Los Angeles, CA
2. Informal routine didactic lectures on heart failure to UCLA medical students at Cedars-Sinai Medical Center, Los Angeles, CA

BIBLIOGRAPHY/PUBLICATIONS

Research Papers – Peer Reviewed:

1. **Geft D**, George J. Circulating Endothelial Progenitor Cells as Angiogenic Signatures in Cardiovascular Disorders. *Expert Review of Cardiovascular Therapy*, Volume 6, Number 8, September 2008, pp. 1115-1121.
2. **Geft D**, Schwartzberg S, Finkelstein A, Ablin J, Maysel-Auslender S, Wexler D, Keren G, George J. Circulating Apoptotic Progenitor Cells in Patients with Congestive Heart Failure. *PLoS ONE* Sept. 18, 2008, 3(9): e3238.
3. **Geft D**, Kobashigawa J. Current concepts for sensitized patients before transplantation. *Curr Opin Organ Transplant*. 2017 Jun; 22(3):236-41.
4. Nikolova AP, Hitzeman TC, Baum R, Caldaruse AM, Agvanyan S, Xie Y, **Geft D**, Chang D, Moriguchi J, Hage A, Azarbal B, Czer LSC, Kittleson M, Patel J, Wu AHB, Kobashigawa J, Hamilton M, Hong TT, Shaw RM. Association of the Plasma Cardiac Bridging Integrator 1 Score, a Novel Diagnostic Biomarker, with Heart Failure with Preserved Ejection Fraction and Cardiovascular Hospitalization. *JAMA Cardiol*. 2018 Dec . 3(12): 1206-1210. PMID: 30383171
5. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators (**Geft, DR**). Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. *N Engl J Med*. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. PMID: 30145929.
6. Kittleson MM, Cole RM, Patel J, Ramzy D, Passano E, Chang DH, **Geft DR**, Czer L, Vescio R, Chung J, Kobashigawa JA, Arabia F, Esmailian F, Moriguchi JD Mechanical circulatory support for cardiac amyloidosis. *Clin Transplant*. 2019: e13663. Epub 2019/07/17. doi: 10.1111/ctr.13663. PubMed PMID: 31309629. 2019 July 15.
7. Robin Mark Shaw, Tara C Hitzeman, Yu Xie, Ronit H Zadikany, Andriana P Nikolova, Rachel Baum, Ana-Maria Caldaruse, Sosse Agvanyan, Gil Y Melmed, Dermot T Mcgovern, **Dael R Geft**, David H Chang, Jaime D Moriguchi, Antoine Hage, Babak Azarbal, Lawrence S Czer, Michelle M Kittleson, Jignesh Patel, Alan H B Wu, Jon A Kobashigawa, Michele Hamilton, TingTing Hong. cBIN1 Score (CS) Identifies Ambulatory HFrefEF Patients and Predicts Cardiovascular Events. 2020 May 25;11:503. doi: 10.3389/fphys.2020.00503. eCollection 2020. PMID: 32670075.
8. Reich H, Ramzy D, Moriguchi J, Dimbil S, Levine R, Passano E, Kittleson M, Cole R, Czer L, Chang D, **Geft D**, Trento A, Chikwe J, Kobashigawa J, Esmailian F. Acceptable Post-Heart Transplant Outcomes Support Temporary MCS Prioritization in the New OPTN|UNOS Heart Allocation Policy. *Transplant Proc*. 2020 Jul 7:S0041-1345(19)31498-8. doi: 10.1016/j.transproceed.2020.04.1819. Online ahead of print. PMID: 32650992.
9. Zadikany RH, Cole RM, Chang DH, Patel JK, **Geft DR**, Czer L, Esmailian F, Ramzy D, Moriguchi JD, Kobashigawa JA, Kittleson MM. Total Artificial Heart as Bridge to Cardiac Replantation. *ASAIO J*. 2020 Jun 29;10.1097/MAT.0000000000001217. doi: 10.1097/MAT.0000000000001217. Online ahead of print. PMID: 32639257.

10. Vaidya GN, Patel JK, Kittleson M, Chang DH, Kransdorf E, **Geft D**, Czer L, Vescio R, Esmailian F, Kobashigawa JA. Intermediate-term Outcomes of Heart Transplantation for Cardiac Amyloidosis in the Current Era. *Clin Transplant*. 2021 Apr 7:e14308. doi: 10.1111/ctr.14308. Epub ahead of print. PMID: 33825224.
11. Patel KJ, Kao T, **Geft D**, Czer L, Esmailian F, Kobashigawa JA, Patel JK. Donor organ evaluation in the era of coronavirus disease 2019: A case of nosocomial infection. *J Heart Lung Transplant*. 2020 Jun;39(6):611-612. doi:10.1016/j.healun.2020.04.005. Epub 2020 Apr 12. PMID: 32334945; PMCID: PMC7152866.
12. Patel KJ, Kao T, **Geft D**, Czer L, Esmailian F, Kobashigawa JA, Patel JK. Donor organ evaluation in the era of coronavirus disease 2019: A case of nosocomial infection. *J Heart Lung Transplant*. 2020 Jun;39(6):611-612. doi:10.1016/j.healun.2020.04.005. Epub 2020 Apr 12. PMID: 32334945; PMCID: PMC7152866.
13. Vaidya GN, Czer LSC, Luthringer D, Kittleson M, Patel J, Chang DH, Kransdorf E, **Geft D**, Azarbal B, Hamilton M, Kobashigawa J. Heart Transplantation for Giant Cell Myocarditis: A Case Series. *Transplant Proc*. 2021 Jan-Feb;53(1):348-352. doi: 10.1016/j.transproceed.2020.10.047. Epub 2020 Dec 29. PMID: 33384178.

Research Papers – Peer Reviewed (In Press): None

Research Papers – Peer Reviewed (Submitted): None

Chapters:

1. **Geft D**, Hage A. Hypertension and Cancer. *Cardio-Oncology: Principles, Prevention and Management*. Book Chapter. 12 December 2016.
2. **Geft D**, Hage A. Pulmonary Hypertension and Cancer. *Cardio-Oncology: Principles, Prevention and Management*. Book Chapter. 12 December 2016.

Letters:

1. Patel KJ, Kao T, **Geft D**, Czer L, Esmailian F, Kobashigawa JA, Patel JK. Donor organ evaluation in the era of coronavirus disease 2019: A case of nosocomial infection. *J Heart Lung Transplant*. 2020 Jun;39(6):611-612. doi: 10.1016/j.healun.2020.04.005.

Reviews: None

Editorials: None

Papers in Preparation (Research Completed): None

Abstracts:

1. **Geft D**, Patel J, Kittleson M, Chang D, Rafiei M, Osborne A, Czer L, Esmailian F, Kobashigawa J. Use of Cylex Immune Monitoring Score to Guide Immunosuppression After Heart Transplantation Reduces Infection Risk. *J Am College of Cardiology*. 2013; 61(10) Suppl A: 196.

2. Wei J, Azarbal B, Cheng R, **Geft D**, Rafiei M, Patel J, Czer L, Kobashigawa J. Cardiac Allograft Vasculopathy is Less Frequent in Contemporary Heart Transplant Population. *J Heart and Lung Transplant*. 2013; 32(4): S209-S210.
3. Kittleson M, Patel J, Hamilton M, Yu Z, Liou F, Yabuno J, Azarbal B, Chang D, **Geft D**, Kobashigawa J. Anti-Thymocyte Globulin Induction to Prevent Renal Dysfunction: Is It Necessary Today? *Am J Transplant*. 2014; 14(S3): 56.
4. Kobashigawa J, Kittleson M, Moriguchi J, Yu Z, Liou F, Luu M, Hamilton M, Chang M, **Geft D**, Esmailian F. How Old Is Too Old for Simultaneous Heart Kidney Donation? *Am J Transplant*. 2014; 14(S3): 425.
5. Kobashigawa J, Kittleson M, Liou F, Shiozaki R, Siddiqui S, Piponniau L, **Geft D**, Hamilton M, Czer L, Reinsmoen, Patel J. The Time Course of Development of Anti-HLA Antibodies Following Heart Transplantation. *J Heart Lung Transplant*. 2015; 34(4): S116.
6. Ghafourian K, Patel J, Kittleson M, Passano E, Liou F, Siddiqui S, Yabuno J, **Geft D**, Chang DH, Czer L, Trento A, Kobashigawa J. Does Time on Ventricular Assist Device Compromise Post-Transplant Outcome? *J Heart Lung Transplant*. 2015; 34(4): S178-179.
7. Kobashigawa J, Kittleson M, Liou F, Shiozaki R, Siddiqui S, Piponniau L, **Geft D**, Hamilton M, Czer L, Reinsmoen N, Patel J. Natural History of Anti-Human Leukocyte Antigen Antibodies after Heart Transplant. *Am J Transplant*. 2015; 15 (suppl 3).
8. Jignesh Patel , Michelle Kittleson , **Dael Geft** , Tamar Aintablian , Yanqing Li , David H Chang , Lawrence Czer , Fardad Esmailian , and Jon Kobashigawa. Chronic Troponin I Leak After Heart Transplantation: What is its Meaning? *Circulation* 2016; 134: A17157.
9. Kobashigawa J, Patel J, Kittleson M, Czer L, Aintablian T, Yang M, Sana S, Rush J, Stimpson E, Geft D, Ramzy D, Reinsmoen N. When a Prospective Crossmatch Is Warranted in the Virtual Crossmatch (VXM) Era. *J Heart Lung Transplant*. 2016; 35(4): S210-211.
10. Kittleson M, Patel J, Czer L, Aintablian T, Rush J, Johnson M, Chang D, Ramzy D, **Geft D**, Kobashigawa J. Are Pediatric Donor Hearts Viable in Adult Recipients? *J Heart Lung Transplant*. 2016; 35(4): S59.
11. Luu M, Patel J, Kittleson M, Czer L, Aintablian T, Norland K, Perry N, Chang D, Hamilton M, **Geft D**, Kobashigawa J. Lower Dose Tacrolimus Monotherapy in Heart Transplant Patients: Is It Safe? *J Heart Lung Transplant*. 2016; 35(4): S281-282.
12. Kittleson M, Patel J, Czer L, Aintablian T, Daun T, Johnson M, Chang D, Trento A, **Geft D**, Kobashigawa J. Outcome of Patients Proceeding to Heart Transplant with Low Level Donor-Specific Antibodies: How Do They Do? *J Heart Lung Transplant*. 2016; 35(4): S281-282.
13. Moriguchi J, Czer L, Henry H, Jocson R, Runyan C, Aintablian T, Passano E, Chang D, **Geft D**, Arabia F. MCS Driveline Infections: Are They Truly Risk Factors for Poor Outcome? *J Heart Lung Transplant*. 2016; 35(4): S257-258.
14. Moriguchi J, Czer L, Henry H, Jocson R, Runyan C, Aintablian T, Passano E, Chang D, **Geft D**, Arabia F. MCS Driveline Infections: Are They Truly Risk Factors for Poor Outcome? *J Heart Lung Transplant*. 2016; 35(4): S257-258.

15. Yang M, Sana S, Rush J, Aintablian T, Kittleson M, **Geft D**, Czer L, Kobashigawa J. C1q Assay is Not Completely Reliable to Predict a Positive Prospective Cytotoxic Donor-Specific Crossmatch Prior to Heart Transplantation. *J Am Coll Cardiol*. 2016; 67 (suppl 13).
16. Zarrini P, Aintablian T, Kittleson M, Chang D, **Geft D**, Czer L, Kobashigawa J. Anti-Thymocyte Globulin Protects Against Ischemia Reperfusion Injury in the Immediate Post Heart Transplant Period. *J Am Coll Cardiol*. 2016; 67 (suppl 13).
17. Jignesh Patel, MD, PhD, Michelle Kittleson, MD, PhD, Xiaohai Zhang, PhD, Ellen Klapper, MD, Kellee Murayama, BS, Tamar Aintablian, BS, Lawrence Czer, MD, **Dael Geft, MD**, David H Chang, MD, and Jon Kobashigawa, MD. Photopheresis Post Heart Transplantation: Does it Portend Poor Outcome? Cedars-Sinai, Los Angeles. Abstract # 2701577. 2017.
18. Jignesh Patel, MD, PhD, Michelle Kittleson, MD, PhD, Lawrence Czer, MD, Tamar Aintablian, BS, Tina Kao, BSN, RN, CCTC, **Dael Geft, MD**, David Chang, MD, Fardad Esmailian, MD, and Jon Kobashigawa, MD. Primary Graft Dysfunction Post Heart Transplantation: Is There Greater Risk for De Novo Donor-Specific Antibody Development? Cedars-Sinai, Los Angeles. Abstract #2701613. 2017.
19. Jignesh Patel, MD, PhD, Michelle Kittleson, MD, PhD, Babak Azarbal, MD, Tamar Aintablian, BS, Genevieve Rodriguez, BA, Michele Hamilton, MD, **Dael Geft, MD**, David Chang, MD, Lawrence Czer, MD, Alfredo Trento, MD, Jon Kobashigawa, MD. Outcome of heart Transplant Patients with Rapidly Progressive Cardiac Allograft Vasculopathy. Cedars-Sinai, Los Angeles. Abstract #2701689. 2017.
20. Leong D, Aintablian T, Patel J, Kittleson M, **Geft D**, Czer L, and Kobashigawa J. Angiographic Dye Prior to Combined Heart-Kidney Donation does not Appear to Harm Donor Kidney Function after Transplant. *J Am Coll Cardiol*. 2017; 69(11): 1430.
21. Heather Barone, Jennifer Hajj, Carmelita Runyan, Newman Huie, Rhodora Jocson, **Dael Geft**, Elizabeth Passano, Lawrence Czer, Jaime Moriguchi, Jon Kobashigawa, and Francisco Arabia. Managing Driveline Repairs in Total Artificial Heart Patients: A Single Center Experience. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S419.
22. David Chang, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Michele Hamilton, **Dael Geft**, Evan Kransdorf, Lawrence Czer, Jon Kobashigawa, Francisco Arabia, and Jaime Moriguchi. Does Socioeconomic Status Impact Outcome following Mechanical Circulatory Support Device Implantation? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S435–S436.
23. David Chang, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Ryan Levine, **Dael Geft**, Evan Kransdorf, Lawrence Czer, Alfredo Trento, Fardad Esmailian, and Jon Kobashigawa. Treatment of Primary Graft Dysfunction with Plasmapheresis Improves Outcome. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S147.
24. Richard Cheng, Danny Ramzy, Babak Azarbal, Fardad Esmailian, **Dael Geft**, David Chang, Elizabeth Passano, Lawrence Czer, Jon Kobashigawa, Jaime Moriguchi, and Francisco Arabia. Clinical Outcomes of Impella Microaxillary Pumps When Used in Patients with Cardiogenic Shock Bridged Successfully to Durable Mechanical Circulatory Support and Cardiac Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S139.
25. Evan Kransdorf, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Angela Velleca, Emily Stimpson, **Dael Geft**, David Chang, Lawrence Czer, Alfredo Trento, and Jon Kobashigawa. Predicted Heart Mass Is

the Optimal Metric for Size Matching in Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S113–S114.

26. Jignesh Patel, Michelle Kittleson, Tamar Aintablian, Ryan Levine, Michelle Curry, Antoine Hage, **Dael Geft**, David Chang, Lawrence Czer, Danny Ramzy, and Jon Kobashigawa. Does the New ISHLT Primary Graft Dysfunction (PGD) Grading Scale in Heart Transplantation Predict Outcome? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S146.
27. Jignesh Patel, Michelle Kittleson, Robert Vescio, Tamar Aintablian, Rayshma Sharoff, Ryan Levine, **Dael Geft**, David Chang, Lawrence Czer, Alfredo Trento, and Jon Kobashigawa. Transthyretin Amyloid Patients > 70 Years of Age Appear as Good Candidates for Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S387.
28. David Chang, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Angela Velleca, Gina Jamero, Evan Kransdorf, **Dael Geft**, Lawrence Czer, Fardad Esmailian, and Jon Kobashigawa. Is Tacrolimus/Proliferation Signal Inhibitor (PSI) Comparable to Cyclosporine/PSI After Heart Transplantation? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S303.
29. Jon Kobashigawa, Michelle Kittleson, Tamar Aintablian, Babak Azarbal, Antoine Hage, Evan Kransdorf, **Dael Geft**, David Chang, Lawrence Czer, Fardad Esmailian, Xiaohai Zhang, Nancy Reinsmoen, and Jignesh Patel. Only Persistent Donor Specific Antibodies Are Associated with Subsequent Cardiac Allograft Vasculopathy after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S292.
30. Jignesh Patel, Michelle Kittleson, Tamar Aintablian, Gabriel Esmailian, Angela Velleca, Antoine Hage, Evan Kransdorf, **Dael Geft**, David Chang, Lawrence Czer, and Jon Kobashigawa, 2017. Despite FDA Black Box Warning, Proliferation Signal Inhibitor (PSI) in the First Year with Induction Therapy Appears Safe in Heart Transplant Patients. *The Journal of Heart and Lung Transplantation*, 36(4), S303–S304.
31. David Chang, Michelle Kittleson, Tamar Aintablian, Lauren Arakawa, Gina Jamero, **Dael Geft**, Evan Kransdorf, Lawrence Czer, Danny Ramzy, and Jon Kobashigawa. Side Effects of Proliferation Signal Inhibitors Limit Their Practical Use After Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S301.
32. Jaime Moriguchi, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, James Kwan, Evan Kransdorf, **Dael Geft**, David Chang, Lawrence Czer, Jon Kobashigawa, and Francisco Arabia. Combined Heart-Kidney Transplant vs Heart Alone Transplant in Patients with Total Artificial Heart: Are they Viable? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S329.
33. David Chang, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Genevieve Rodriguez, Ryan Levine, **Dael Geft**, Evan Kransdorf, Lawrence Czer, Fardad Esmailian, and Jon Kobashigawa. Coronary Vasospasm after Heart Transplantation: Does it Portend Poor Outcome? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S294.
34. Andriana Nikolova, **Dael Geft**, David Chang, Joshua Chung, Rhodora Jocson, Tamar Aintablian, Elizabeth Passano, Lawrence Czer, Jon Kobashigawa, Jaime Moriguchi, and Francisco Arabia. What Factors Influence Right Ventricular Function Improvement in the Setting of Pulmonary Arterial Pressure Normalization After Left Ventricular Assist Device Placement? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S351–S352.

35. Jon Kobashigawa, Michelle Kittleson, Tamar Aintablian, David Chang, **Dael Geft**, Lawrence Czer, Fardad Esmailian, and Jignesh Patel. The Outcome of Heart Transplant Patients with Hemodynamic Compromise Rejection in the Current Era. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S288–S289.
36. **Dael Geft**, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Ryan Levine, Michael Hashimoto, Evan Kransdorf, David Chang, Lawrence Czer, Danny Ramzy, and Jon Kobashigawa. The Story on Extracorporeal Membrane Oxygenation (ECMO) Directly to Mechanical Circulatory Support or to Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S336–S337.
37. Jon Kobashigawa, Michelle Kittleson, Sean Sana, Tamar Aintablian, Ryan Levine, Babak Azarbal, **Dael Geft**, David Chang, Lawrence Czer, Daniel Luthringer, and Jignesh Patel. Correlation of the Grades of Antibody-Mediated Rejection to 1-Year IVUS results after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S288.
38. Dominick Megna, Fardad Esmailian, Jignesh Patel, Michelle Kittleson, Tamar Aintablian, Emily Stimpson, Evan Kransdorf, **Dael Geft**, David Chang, Lawrence Czer, and Jon Kobashigawa. Success for Combined Heart and Kidney Transplantation. *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S229.
39. Frank Liou, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Tina Kao, Evan Kransdorf, **Dael Geft**, David Chang, Lawrence Czer, Danny Ramzy, and Jon Kobashigawa. Donor Heart Diastolic Dysfunction: Do You Take This Heart for Transplantation? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S43.
40. Michael Johl, Jignesh Patel, Michelle Kittleson, Lawrence Czer, Tamar Aintablian, Angela Velleca, Michele Hamilton, **Dael Geft**, David Chang, Danny Ramzy, and Jon Kobashigawa. ACE Inhibitors or ARBs - Do They Improve Outcome After Heart Transplantation? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S234–S235.
41. **Dael Geft**, Michelle Kittleson, Jignesh Patel, Tamar Aintablian, Kristen Yabuno, Brenda Kearney, Evan Kransdorf, David Chang, Lawrence Czer, Alfredo Trento, and Jon Kobashigawa. Severe Tricuspid Regurgitation After Heart Transplantation: Does It Require Surgical Repair? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S223–S224.
42. Jignesh Patel, Michelle Kittleson, Tamar Aintablian, James Kwan, Nena Musto, Brenda Kearney, **Dael Geft**, David Chang, Lawrence Czer, Fardad Esmailian, and Jon Kobashigawa. Donor Heart Turn Down in the Field: What's Going On? *The Journal of Heart and Lung Transplantation*, 2017. 36(4), S44.
43. Kransdorf E, Kittleson M, Patel J, Aintablian T, Levine R, Kearney B, Musto N, Hage A, **Geft D**, Czer L, Esmailian F, Trento A, Kobashigawa J. Risk of Amiodarone and Permanent Pacemaker Placement After Heart Transplantation. *Am J Transplant*. 2017;17 (suppl 3).
44. Leong D, Azarbal B, Patel J, Kittleson M, Czer L, Aintablian T, Chang D, **Geft D**, Kobashigawa J. In the Modern Era, Cytomegalovirus Does Not Appear to Increase Intimal Thickening After Heart Transplantation. *Am J Transplant*. 2017;17 (suppl 3).
45. Patel J, Kittleson M, Czer L, Aintablian T, Stimpson E, Azarbal B, **Geft D**, Chang D, Esmailian F, Kobashigawa J. Post-Transplant Sensitization: Does it Make a Difference in the Development of First-Year Intimal Thickening? *Am J Transplant*. 2017;17 (suppl 3).

46. Patel J, Kittleson M, Czer L, Aintablian T, Kao T, **Geft D**, Chang D, Esmailian F, Kobashigawa J. Primary Graft Dysfunction Post Heart Transplantation: Is There Greater Risk for De Novo Donor-Specific Antibody Development? *Am J Transplant*. 2017;17 (suppl 3).
47. Patel J, Kittleson M, Zhang X, Klapper E, Aintablian T, Murayama K, Czer L, **Geft D**, Chang D, Kobashigawa J. Photopheresis for Recalcitrant Rejection After Heart Transplantation: Worthwhile? *Am J Transplant*. 2017;17 (suppl 3).
48. David Chang, MD, Michelle Kittleson, MD, PhD, Jignesh Patel, MD, PhD, Tamar Aintablian, BS, Ryan Levine, BS, Newman Huie, BSN, Evan Kransdorf, MD, PhD, **Dael Geft, MD**, Lawrence Czer, MD, Jon Kobashigawa, MD, Francisco Arabia, MD, MBA, and Jaime Moriguchi, MD. Weight Loss in Patients with Left Ventricular Assist Device Positioned Above or Below the Diaphragm for Patients with Severe Heart-Failure: Does it Make a Difference? *ASAIO Journal* 2017. Cedars-Sinai, Los Angeles
49. Levine R., Patel J., Levine M., Kittleson M., Kransdorf E., Dimbil S., **Geft D.**, Chang D., Czer L., Kobashigawa J. Incidence of Pneumonitis in Heart Transplant Patients Started on a Proliferation Signal Inhibitor *Am J Transplant*. 2017;17 (suppl 3).
50. Kransdorf E., Patel J., Kittleson M., Levine R., Dimbil S., **Geft D.**, Chang D., Czer L., Kobashigawa J. Late Donor-Specific Antibody (Especially Class II) Development is Associated with an Increased Risk for Cardiac Allograft Vasculopathy *Am J Transplant*. 2017;17 (suppl 3)
51. Velleca A., Kransdorf E., Patel J., Kittleson M., Dimbil S., Levine R., **Geft D.**, Chang D., Czer L., Kobashigawa J. Do Recent Heart Transplant Patients Need to Reside Close to the Transplanting Center? A Look at the Impact of Commuting Times on Clinical Outcomes *Am J Transplant*. 2017;17 (suppl 3)
52. Patel J., Kittleson M., Kransdorf E., Levine R., Dimbil S., **Geft D.**, Chang D., Czer L., Kobashigawa J. IVIG Induction May Be Helpful in Highly Sensitized Patients after Heart Transplantation *Am J Transplant*. 2017;17 (suppl 3).
53. Kittleson M., Patel J., Kransdorf E., Dimbil S., Levine R., Mersola S., **Geft D.**, Chang D., Czer L., Kobashigawa J. Decreased Post Heart Transplant Survival with Epstein-Barr Virus Mismatch in the Current Era *Am J Transplant*. 2017;17 (suppl 3)
54. Patel J., Kittleson M., Kransdorf E., Dimbil S., Levine R., **Geft D.**, Chang D., Czer L., Kobashigawa J. The Combination of pAMR and Circulating Donor-Specific Antibodies is Even More Associated with Cardiac Allograft Vasculopathy after Heart Transplant *Am J Transplant*. 2017;17 (suppl 3)
55. Patel J., Kittleson M., Kransdorf E., Levine R., Dimbil S., **Geft D.**, Chang D., Czer L., Kobashigawa J. Pre-Transplant Memory Patients Even without Detected Antibody Are at Rejection Risk in the First-Year after Heart Transplantation *Am J Transplant*. 2017;17 (suppl 3).
56. Kittleson M., Patel J., Kransdorf E., Dimbil S., Levine R., **Geft D.**, Chang D., Czer L., Sharoff R., Kobashigawa J. The Renal Sparing Protocol after Heart Transplant That Keeps Giving *Am J Transplant*. 2017;17 (suppl 3)
57. Kransdorf E., Patel J., Kittleson M., Levine R., Dimbil S., **Geft D.**, Chang D., Czer L., Kobashigawa J. Assessing Response to Desensitization: What Makes Sense? *Am J Transplant*. 2017;17 (suppl 3).

58. Kittleson M., Patel J., Kransdorf E., Dimbil S., Levine R., **Geft D.**, Chang D., Czer L., Kobashigawa J. Cardiac MRI May Help to Determine When to Refer Heart Transplant Patients for Redo Heart Transplant Am J Transplant. 2017;17 (suppl 3)
59. Kransdorf E., Patel J., Kittleson M., Dimbil S., Levine R., **Geft D.**, Chang D., Czer L., Kobashigawa J. The Overriding Importance of HLA-DR Donor-Specific Antibody That is Correlated to CAV after Heart Transplant Am J Transplant. 2017;17 (suppl 3).
60. Kittleson M., Patel J., Kransdorf E., Dimbil S., Levine R., **Geft D.**, Chang D., Czer L., Kobashigawa J., Garg R., Zahn E. Heart Transplantation in Patients with Complex Congenital Heart Disease Am J Transplant. 2017;17 (suppl 3)
61. Kittleson M., Patel J., Kransdorf E., Levine R., Dimbil S., **Geft D.**, Chang D., Czer L., Kobashigawa J. What Threshold MFI is the Luminex 1:8 Dilution the Poor Man's C1q for Patients Awaiting Heart Transplant? Am J Transplant. 2017;17 (suppl 3)
62. Patel J., Kittleson M., Kransdorf E., Levine R., Dimbil S., **Geft D.**, Chang D., Czer L., Kobashigawa J. Liver Biopsy Fibrosis Not Liver Imaging Predicts Survival after Heart Transplant Am J Transplant. 2017;17 (suppl 3)
63. Kittleson M., Patel J., Kransdorf E., Levine R., Dimbil S., **Geft D.**, Chang D., Czer L., Kobashigawa J. The Secret is Selection of Muscular Dystrophy for Success after Heart Transplant Am J Transplant. 2017;17 (suppl 3).
64. Patel J., Kittleson M., Kransdorf E., Dimbil S., Levine R., **Geft D.**, Chang D., Czer L., Kobashigawa J. The Continuous Debate of Older Donors into Older Recipients: Another Angle Am J Transplant. 2017;17 (suppl 3).
65. Patel J., Kittleson M., Kransdorf E., Levine R., Dimbil S., **Geft D.**, Chang D., Czer L., Kobashigawa J. Is Renal Function after Heart Transplantation an Issue for Patients with Cardiac Amyloidosis? Am J Transplant. 2017;17 (suppl 3).
66. Rafiei M., Patel J., Kransdorf E., Levine R., Dimbil S., Mersola S., Esmailian G., **Geft D.**, Chang D., Czer L., Kobashigawa J. Outcomes of C4d+ Immunostaining in Heart Transplantation: Is All Immunologic AMR Bad? Am J Transplant. 2017;17 (suppl 3).
67. Rachel Baum, Bing Xu, Yu Xie, Ronit Zadikany, Tara Hitzeman, Sosse Agvanyan, **Dael Geft**, David Chang, Jaime Moriguchi, Antoine Hage, Babak Azarbal, Lawrence Czer, Michelle Kittleson, Jignesh Patel, Jon Kobashigawa, Michele Hamilton, TingTing Hong, and Robin M Shaw. Plasma Based cBIN1 Correlates with Myocardial Health in Heart Failure with Reduced Ejection Fraction. Circulation Research, 2017; 121 (suppl 1).
68. F. Esmailian, F. Arabia, L. Czer, M. Kittleson, **D. Geft**, R. Cole, G. Esmailian, M. Rafiei, E. Passano, H. Barone, J. Moriguchi. Does the Type of Mechanical Circulatory Support as a Bridge to Heart Transplant Affect Outcome after Transplant? The Journal of Heart and Lung Transplantation. 2018; 37(4): S289.
69. J. Patel, M. Kittleson, L. Czer, **D. Geft**, S. Dimbil, R. Levine, B. Kearney, E. Kransdorf, F. Esmailian, J. A. Kobashigawa. In Sensitized Pre-Transplant Patients Does IVIG After Heart Transplant Have Any Benefit? The Journal of Heart and Lung Transplantation 2018; 37(4): S440.

70. Velleca, J. Patel, M. Kittleson, L. Czer, D. H. Chang, S. Dimbil, R. Levine, A. Patel, **D. Geft**, A. Hage, T. Kao, J. A. Kobashigawa. Cedars. Does Commuting Time to the Transplant Center Affect Compliance with Visits and Outcome after HTx in a big Metropolitan Area? *The Journal of Heart and Lung Transplantation*, 2018; 37(4): S343.
71. M. Kittleson, J. Patel, L. Czer, D. Chang, S. Dimbil, R. Levine, N. Lam, R. Bleiker, **D. Geft**, D. Ramzy, X. Zhang, D. Luthringer, J. A. Kobashigawa. Pathology Antibody-Mediated Rejection Plus Circulating Donor-Specific Antibodies Increase Development of Cardiac Allograft Vasculopathy after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2018; 37(4): S437–S438.
72. F. Esmailian, S. Dimbil, R. Levine, M. Kittleson, R. Cole, L. Czer, D. Chang, **D. Geft**, J. Chung, D. Ramzy, J. Moriguchi, J. Kobashigawa. Acceptable Post-Heart Transplant Outcomes Support Temporary MCS as Status 2 for the New UNOS Donor Heart Allocation Policy. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S431.
73. M. Kittleson, J. Patel, D.H. Chang, **D. Geft**, S. Dimbil, R. Levine, B. Kearney, L. Czer, M. Hamilton, A. Trento, J.A. Kobashigawa. Heart Transplantation in Muscular Dystrophy: Selection is Crucial for Success. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S396-396.
74. F. Esmailian, S. Dimbil, R. Levine, M. Kittleson, R. Cole, L. Czer, D. Chang, **D. Geft**, J. Chung, D. Ramzy, J. Moriguchi, J. Kobashigawa. Temporary MCS versus Durable MCS as a Bridge to Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S344.
75. S. Dimbil, J. Patel, B. Azarbal, M. Kittleson, D.H. Chang, **D. Geft**, R. Levine, L. Czer, J. Chung, F. Esmailian, J.A. Kobashigawa. Is Left Main Stenting Long-Term after Heart Transplantation Worthwhile? *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S395.
76. M Kittleson, J. Patel, R. Cole, **D. Geft**, S. Dimbil, R. Levine, S. Mersola, L. Czer, B. Azarbal, R. Zabner, P. Zakowski, J.A. Kobashigawa. Does Thymoglobulin Induction Lead to Increased CMV Infection after Heart Transplantation in the Current Tacrolimus Era. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S310-S31.
77. R. Levine, J. Patel, M. Kittleson, **D. Geft**, E. Kransdorf, S. Dimbil, E. Passano, S. Sana, L. Czer, A. Hage, D. Ramzy, J.A. Kobashigawa. Does the Model for End-Stage Liver Disease Predict Primary Graft Dysfunction? *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S297.
78. D.H. Chang, M. Kittleson, J. Patel, **D. Geft**, R. Levine, S. Dimbil, K. Nishihara, T. Kao, L. Czer, A. Trento, J.A. Kobashigawa. Short and Stout Female Donors in Heart Transplantation: Do They Make a Difference? *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S270.
79. Dimbil S, Kittleson M, Patel J, **Geft D**, Cheng R, Levine R, Sato T, Czer L, Zabner R, Zakowski P, Kobashigawa JA, Azarbal B. Does Cytomegalovirus Truly Increase Cardiac Allograft Vasculopathy via First-Year Intravascular Ultrasound after Heart Transplant in the Tacrolimus Era? *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S283-284.
80. D.H. Chang, J. Patel, M. Kittleson, **D. Geft**, S. Dimbil, R. Levine, C. Kawata, L. Czer, J. Moriguchi, D. Ramzy, J.A. Kobashigawa. Mechanical Circulatory Support Patients Awaiting Heart Transplant with Positive AT1R Antibodies Have Acceptable Outcome Post-Heart Transplant. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S210-S211.

81. M. Kittleson, J. Patel, E. Kransdorf, **D. Geft**, S. Dimbil, R. Levine, A. Velleca, L. Czer, A. Hage, R. Zabner, P. Zakowski, J. Kobashigawa. Undue Infection Risk from Proliferation Signal Inhibitors When Initiated Later after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, 2019; 38(4): S311.
82. Maulin B. Shah, Aaron Yung, Joseph Ebinger, James Mirocha, Edmund Huang, **Dael Geft**, Alice Peng and Babak Azarbal. Impact of Percutaneous Coronary Intervention in Renal Transplant Candidates on Long Term Cardiac Outcomes. *Journal of the American College of Cardiology*. Volume 75, Issue 11 Supplement 1, March 2020.
83. M. Kittleson, J. Patel, E. Kransdorf, A. Shen, K. Nishihara, S. Rajkumar, A. Velleca, **D. Geft**, L. Czer, J. Moriguchi and J. Kobashigawa. Desensitization Therapy for Mechanical Circulatory Support Patients with Existing Driveline Infection: Is It Safe with Current Desensitization Therapies? *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
84. O. Seguchi, J. Youn, **D. Geft**, R. Cole, A. Shen, K. Nishihara, S. Mersola, C. Runyan, J. Hajj, D. Ramzy, J.A. Kobashigawa and J. Moriguchi. The Burden of Total Artificial Heart Patients and Complications after Heart Transplantation. *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
85. M. Kittleson, J. Patel, E. Kransdorf, A. Shen, K. Nishihara, G. Jamero, S. Sana, A. Hage, **D. Geft**, L. Czer, F. Esmailian and J.A. Kobashigawa. Is Anti-Thymocyte Globulin for Sensitized Patients Undergoing Heart Transplantation Effective? *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
86. J. Youn, O. Seguchi, R. Cole, **D. Geft**, K. Nishihara, A. Shen, R. Sharoff, D. Ramzy, J. Kobashigawa and J. Moriguchi. Desensitization in Mechanical Circulatory Support Patients Awaiting Heart Transplantation: What is the Post-Transplant Outcome? *The Journal of Heart and Lung Transplantation*, Vol 39, No 4S, April 2020.
87. Nishihara K, Patel J, Kittleson M, Chang D, Kransdorf E, **Geft D**, Shen A, Czer L, Esmailian F, Kobashigawa JA. Do the Characteristics of Donor Specific Antibody Truly Predict Severity of Cardiac Allograft Vasculopathy Late after Transplantation? *Am J Transplant*. 2020; 20 (suppl 3).
88. Kobashigawa JA, Kittleson M, Patel J, Chang D, Kransdorf E, **Geft D**, Nishihara K, Shen A, Czer L, Esmailian F. High-Risk Antibodies Pre-Transplant Impacts Outcome after Heart Transplantation. *Am J Transplant*. 2020; 20 (suppl 3).
89. Shen A, Patel J, Kittleson M, Chang D, Kransdorf E, **Geft D**, Nishihara K, Czer L, Esmailian F, Kobashigawa JA. The Frequency of De Novo DSA in the Years Following Heart Transplantation. *Am J Transplant*. 2020; 20 (suppl 3).
90. Patel J, Kittleson M, Chang D, Kransdorf E, **Geft D**, Shen A, Nishihara K, Velleca A, Czer L, Esmailian F, Kobashigawa JA. Is Ischemia Reperfusion Injury Immediately after Heart Transplantation Correlated to Increased Intimal Thickening in the First Year? *Am J Transplant*. 2020; 20 (suppl 3).

91. Kittleson M, Patel J, Chang D, Kransdorf E, **Geft D**, Nishihara K, Shen A, May B, Czer L, Esmailian F, Kobashigawa JA. Is 3-4+ Liver Fibrosis a Contraindication to Heart Transplantation? *Am J Transplant.* 2020; 20 (suppl 3).
92. Patel J, Kittleson M, Chang D, Kransdorf E, **Geft D**, Shen A, Nishihara K, Jamero G, Czer L, Esmailian F, Kobashigawa J. Effects of Donor Heavy Alcohol Use on Post-Heart Transplant Outcomes: Time to Abstain? *Am J Transplant.* 2020; 20 (suppl 3).
93. Kobashigawa JA, Kittleson M, Patel J, Chang D, Kransdorf E, **Geft D**, Nishihara K, Shen A, Czer L, Esmailian F. High-risk Antibodies Pre-transplant Impact Outcome After Heart Transplantation. *Am J Transplant.* 2020; 20 (Supplement 3).
94. Kittleson M, Patel J, Chang D, Kransdorf E, **Geft D**, Nishihara K, Shen A, Velleca A, Czer L, Esmailian F, Kobashigawa JA. Challenging Dogma that Anti-thymocyte Globulin Induction with Delated Calcineurin Inhibitor Benefits Patients with Renal Insufficiency Undergoing Heart Transplant. *Am J Transplant.* 2020; 20 (Supplement 3).